A VC firm is expressly focused on funding ophthalmic innovation. The firm invests in therapeutics, devices, and diagnostics that improve and preserve vision. The firm looks to identify and bring forward early stage investments with our deep knowledge of the space. The firm is currently allocating $100k-$750k+ utilizing convertible notes and equity in early stage companies (seed to Series B). The firm will both lead and co-invest as part of a syndicate. The firm is currently seeking new opportunities based in North America and Europe.
The firm specializes in early-stage investments in innovative ophthalmic diagnostic and treatment solutions. The firm seeks to invest in a broad range of technologies applicable to ophthalmology, including small molecule and biologic therapeutics, low and high-risk medical devices, diagnostics, drug delivery, and software solutions. The firm would also consider generic drugs but with less interest. The firm considers companies at all stages, but prefers early stage projects with some clinical or other supporting data where it can add meaningful expertise outside of financial capital.
The firm seeks management teams formed by experienced entrepreneurs with track records of success and scientists with domain expertise in their field. The firm opportunistically seeks board seats on a deal-by-deal basis particularly in situations where they can add meaningful value.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment